IR@PKUHSC  > 北京大学临床肿瘤学院  > 胸部肿瘤内科
学科主题临床医学
Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer
Wang, Xin1; Zhao, Jun1; Yang, Lu1; Mao, Li2; An, Tongtong1; Bai, Hua1; Wang, Shuhang1; Liu, Xuyi1; Feng, Guoshuang3; Wang, Jie1
关键词Ercc1 Rrm1 Nsclc Platinum-based Chemotherapy
刊名MEDICAL ONCOLOGY
2010-06-01
DOI10.1007/s12032-009-9239-3
27期:2页:484-490
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]MESSENGER-RNA EXPRESSION ; GEMCITABINE ; CISPLATIN ; SURVIVAL ; RRM1 ; CHEMOTHERAPY ; REPAIR ; LINES
英文摘要

The goal of this study is to determine role of excision repair cross-complementing group 1 gene (ERCC1) and ribonucleotide reductase subunit M1 (RRM1) expression in predicting response and survival in Chinese patients with advanced stage non-small cell lung cancer (NSCLC) treated with platinum-based chemotherapy. Formalin-fixed, paraffin-embedded biopsy tissues were retrospectively obtained from 124 advanced NSCLC patients. Protein expression levels of ERCC1 and RRM1 were determined by immunohistochemistry (IHC). Associations between expression of ERCC1 and RRM1 and clinic-pathologic parameters were analyzed. The study shows that ERCC1 and RRM1 expression was detected in 43 (35%) and 50 (40%) of the 124 tumor samples, respectively. Expression of ERCC1 and RRM1 was negatively associated with tumor response. Fifty-four percent patients whose tumors did not express ERCC1 had partial response (PR) compared to 33% whose tumors expressed the protein (P = 0.022). Similarly, 54% patients whose tumor did not express RRM1 had PR compared to 36% whose tumors expression the protein (P = 0.042). Further, patients whose tumors lacked of ERCC1 but not RRM1 expression had a longer median survival time than those tumors expressed ERCC1 (13.4 months versus 9.1 months; P = 0.006), which is independent of other prognostic factors (P = 0.0066). In conclusion, tumor ERCC1 expression is associated with tumor response and patients′ survival in Chinese advanced NSCLC patients treated with platinum-based regimen and may serve as a biomarker in predicting tumor response and clinical outcome in the patient population.

语种英语
WOS记录号WOS:000277203200050
项目编号2006AA02A401 ; 30772472 ; 2-013-39
资助机构National High Technology Research and Development Program of China ; Capital Development Foundation ; Peking University
引用统计
被引频次:26[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/55932
专题北京大学临床肿瘤学院_胸部肿瘤内科
作者单位1.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Thorac Med Oncol, Beijing 100036, Peoples R China
2.Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
3.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Biostat, Beijing 100036, Peoples R China
推荐引用方式
GB/T 7714
Wang, Xin,Zhao, Jun,Yang, Lu,et al. Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer[J]. MEDICAL ONCOLOGY,2010,27(2):484-490.
APA Wang, Xin.,Zhao, Jun.,Yang, Lu.,Mao, Li.,An, Tongtong.,...&Wang, Jie.(2010).Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer.MEDICAL ONCOLOGY,27(2),484-490.
MLA Wang, Xin,et al."Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer".MEDICAL ONCOLOGY 27.2(2010):484-490.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wang, Xin]的文章
[Zhao, Jun]的文章
[Yang, Lu]的文章
百度学术
百度学术中相似的文章
[Wang, Xin]的文章
[Zhao, Jun]的文章
[Yang, Lu]的文章
必应学术
必应学术中相似的文章
[Wang, Xin]的文章
[Zhao, Jun]的文章
[Yang, Lu]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。